Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

16-Hour fast may sharpen aging brains, small study hopes

NCT ID NCT05732935

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This study tests whether time-restricted eating (fasting for 16 hours each day) can improve memory, thinking, and overall well-being in overweight adults aged 65 and older who are worried about their memory. Over 24 weeks, participants either follow the fasting plan or join a healthy aging group. The goal is to see if this simple lifestyle change can help protect the brain as we age.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
time-restricted eating (16-hour daily fasting)
What this could lead to
If it works, this could point toward a simple, drug-free way to help protect memory and thinking in older adults who are overweight.
What could go wrong
This is a small, early-stage study with only 52 participants. The results may not apply to everyone, and sticking to a 16-hour fast every day can be hard to maintain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

45 people

The number who actually took part.

Started

Mar 2023

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 65 years; * Body Mass Index (BMI \> 25 kg/m2) * Normal age-, gender-, and education-adjusted performance on TICS-M (Telephone Interview for Cognitive Status) * Responds yes to questions 1 (memory worse), 2 (word finding difficulties) or 3 (planning/organization difficulties) on the Subjective Cognitive Decline Questionnaire * Reports onset of cognitive difficulties in past five years * Reports they believe they are worse than others their age OR they have talked to a clinician about it. * Provides informed consent and willing to be randomized to either intervention group. Exclusion Criteria: * Failure to provide informed consent; * Recent History or clinical manifestation of cardiovascular disease, diabetes, cholelithiasis, liver or renal disease, cancer, or progressive, degenerative neurologic disease (e.g., Parkinson's Disease, multiple sclerosis, ALS) * Abnormal laboratory markers (e.g., renal or liver abnormalities, elevated potassium levels, or hemoglobin and hematocrit below the lower limit of normal) as determined by study physician. * Significant cognitive impairment, defined as a scores below the cutoff for dementia on TICS-M * Severe rheumatologic or orthopedic diseases (e.g., awaiting joint replacement, active inflammatory disease); * Terminal illness with life expectancy less than 12 months, as determined by a physician; * Other significant co-morbid disease (e.g. renal failure on hemodialysis) or severe psychiatric disorder (e.g. bipolar, schizophrenia); * Current use of anabolic medications (i.e., growth hormones or testosterone), antidepressant medications, antipsychotic agents, monoamine oxidase inhibitors, anticholinesterase inhibitors (i.e., Aricept), anticoagulant therapies (aspirin use is permitted), or antibiotics; * Excessive alcohol use (\>14 drinks per week); * History of drug or alcohol abuse (i.e., more than 5 drinks/day for males or more than 4 drinks/day for females); * Planning to permanently leave the area in the next year; * History of pulmonary disease, pneumonitis or interstitial lung disease; * Current smoker or less than 3 years quit; * Creatinine clearance \< 30 ml/minute by estimated Glomerular Filtration Rate (eGFR); * Fasting \>12 hours per day * Actively trying to lose weight by participating in formal weight loss program or significantly restricting calorie intake or weight loss \> 5 lbs in the past month * Resting heart rate of \>120 beats per minute, systolic blood pressure \> 180 mmHg or diastolic blood pressure of \> 100 mmHg * Unstable angina, heart attack or stroke in the past 3 months * Continuous use of supplemental oxygen to manage a chronic pulmonary condition or heart failure * Rheumatoid arthritis, Parkinson's disease or currently on dialysis * Insulin dependent diabetes mellitus * Taking medications that preclude fasting for 16 hours (e.g. must be taken with food at least 12 hours apart) * Participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment * Any condition that in the opinion of the investigator would impair ability to participate in the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical and Translational Research Building - Institute on Aging Suite

    Gainesville, Florida, 32603, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.